Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--( BUSINESS WIRE )--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company's ambitious commitments to minimize its environmental footprint.

Teva's Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Pfizer

Vertex Pharmaceuticals

Bargains can easily be found as the new year gets underway.

3 Dirt Cheap Stocks to Buy in January

TEL AVIV, Israel & PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA ) 41st Annual J.P.

Teva Pharmaceutical Industries Ltd. (TEVA) Presents at 41st Annual J.P.

With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.

TEVA Shares Rise on Broad Support for Opioids Settlement

Teva Pharmaceutical Industries Ltd. (TEVA) witnessed a jump in share price last session on above-average trading volume.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Jumps 5.5%: Will It Continue to Soar?

TEL AVIV, Israel & PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed a sufficient level of participation to move forward with its nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. Teva has either already settled with or confirmed participation from 48 of the 50 states and will continue to pursue participation by those states that have yet to join. The sign-on process for the states' subdivisions will now begin. Given the very positive response from states, the Company remains optimistic that the nationwide settlement will garner similar support from the states' subdivisions.

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States

TEL AVIV, Israel & PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time).

Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference

PetMed Express

Sometimes, business models that sound safe still fail to deliver for shareholders.

2 "Safe" Stocks That Are Anything But

Shares look to have been undergoing a bottoming pattern for well over three years now. Although near-term EPS revisions have been faltering, Teva's relationship between its valuation and profitability points to an undervalued stock.

Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year

First Majestic Silver

Bank of America

Pinterest

SSR Mining

This mix of growth and value stocks can outperform in a challenging environment.

My Top 5 Portfolio Holdings for 2023

Amazon

Alphabet

These three leading companies are ripe for the picking and may never be this cheap again.

3 Unparalleled Stocks to Buy That Have Never Been This Cheap

Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.

Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO

TEL AVIV, Israel & PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the company has finalized the documentation of its proposed nationwide opioid settlement with both the working group of States' Attorneys General and the Multi-District Litigation Plaintiffs' Executive Committee. Allergan has also finalized its settlement terms. As announced during the Company's third quarter earnings call, Teva and Allergan have resolved their dispute with respect to Teva's indemnification obligations.

Teva Finalizes Nationwide Opioid Settlement Terms

Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer – aiming to increase their share of an expanding market.

Generic drugmakers Teva and Sandoz make major push to biosimilars

Teva Pharmaceutical Industries Ltd  (NYSE:TEVA) is down 2.1% at $8.54 at last check, after the company named former Novartis (NVS) and Biogen (BIIB) executive Richard Francis as its new chief executive officer, effective after the retirement of CEO Karen Schultz later this year.

C-Suite Shakeup Pressures Teva Pharmaceutical Stock

Teva Pharmaceuticals (NYSE: TEVA ) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. Francis will take over as the president and CEO of Teva Pharmaceuticals starting on Jan. 1, 2023.

TEVA Stock Alert: What to Know About Teva Pharmaceuticals' New CEO

Teva Pharmaceutical Industries Ltd. TEVA, +0.93% on Monday said its current CEO Kåre Schultz will retire on Dec. 31.

Teva names former Sandoz chief Richard Francis as new CEO

TEL AVIV, Israel--( BUSINESS WIRE )--Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company's Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022.

Teva Announces Appointment of Richard Francis as President and CEO

Teva Pharmaceutical was able to achieve a nationwide settlement to the opioid crisis, proving the ability of the company's management to overcome difficulties. Teva Pharmaceutical's provision for legal settlements and loss contingencies was $4,077 million in Q3 2022, up 103% year-over-year.

Teva Pharmaceutical: Warren Buffett Likely Made A Mistake Selling Shares

PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives.

Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform

PARSIPPANY, N.J.--( BUSINESS WIRE )--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a new collaboration with HealthSnap, a leading full-service Virtual Care Management Platform for chronic disease management.

Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

Eli Lilly

Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.

Eli Lilly ordered to pay $176.5 mln to Teva in U.S. migraine drug patent trial

Antero Midstream Partners

Ford Motor Company

Green Thumb Industries Inc.

Okta

You don't need a large pile of cash to begin building wealth on Wall Street.

Adding $100 to These 5 Stocks Would Be a Genius Move Right Now

Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting

News for Teva Pharmaceutical Stock (TEVA)